Q2 2026 Abbott Laboratories Earnings Call Transcript
Key Points
- Abbott Laboratories (ABT) reported a sales growth of 4.8% in the second quarter, marking an acceleration compared to previous quarters.
- The company exceeded the midpoint of its guidance range with adjusted earnings per share of $1.31.
- Abbott Laboratories (ABT) raised its full-year EPS guidance range to $5.45 to $5.60.
- The company is launching several new products, including the Libre Duo, a dual glucose ketone monitoring sensor, and the TactiFlex Duo PFA catheter.
- Abbott Laboratories (ABT) is seeing strong performance in its EPD segment, with sales growth of 9% driven by demand in emerging markets.
- Sales in Rapid and Molecular Diagnostics declined by 8% due to a weaker than normal respiratory virus season.
- The company faces challenges in the US mitral space within its Structural Heart unit, impacting growth.
- Abbott Laboratories (ABT) is experiencing competitive intensity in the mitral segment in the US.
- The company is still forecasting a decline in its China business due to the impact of VBP (Volume-Based Procurement).
- Growth in the Continuous Glucose Monitoring (CGM) segment has plateaued at 9.5%, with future acceleration dependent on reimbursement expansions.
Good morning, and thank you for standing by. Welcome to Abbott's second-quarter 2026 earnings conference call.
(Operator Instructions)
This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.
Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
